

## Original Article

# Geographical distribution affects survival of patients with intracranial ependymoma in the USA: a SEER based study

Xinxin Ji<sup>1,3\*</sup>, Xuedi Yu<sup>1,3\*</sup>, Ping Li<sup>1,3</sup>, Li Ma<sup>1</sup>, Xun Jin<sup>2</sup>, Wenliang Li<sup>1</sup>

<sup>1</sup>Department of Neurosurgery, <sup>2</sup>Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Hospital and Institute, Key Laboratory of Cancer Prevention and Therapy of Tianjin, National Clinical Research Center for Cancer, Tianjin 300060, China; <sup>3</sup>Tianjin Medical University, Tianjin 300060, China. \*Equal contributors.

Received January 1, 2019; Accepted April 19, 2019; Epub June 15, 2019; Published June 30, 2019

**Abstract:** Precision medicine, based on the relationship between personalized clinical characteristics and prognosis, leads to better patient therapeutic outcomes. Social factors directly affect patient prognosis in several cancers. However, the relationship between social factors and prognosis of patients with intracranial ependymoma (IE) remains unclear. The aim of this retrospective study was to identify the association between social factors and IE patient prognosis. Information was collected from patients histologically confirmed to have IE between 1973 and 2015, analyzing the relationship between patients and social factors using the Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier and Cox's proportional hazards regression analyses were used to evaluate patient survival. Present results revealed that geographical distribution was statistically significantly associated with prognosis of IE patients, based on the SEER database. Patients from the Midwest region of the USA had a lower 5-year survival rate (64.8%) than those from the Northeast (74.8%), South (79.6%), and West (72.0%). Reducing bias, propensity score matching was further applied in analyzing relevant factors. Similarly, prognosis in the Midwest region (hazard ratio [HR] = 1) was poorer than that in the Northeast (HR = 0.62), South (HR = 0.55), and West (HR = 0.71). Therefore, geographical distribution may play an important role in the malignant progression of IE and may be beneficial for the precise treatment of patients with IE.

**Keywords:** Intracranial ependymoma, geographical distribution, prognosis, SEER, 5-year survival rate


## Introduction

Intracranial ependymomas (IEs) are rare gliomas found in the central nervous system [1]. IE's originate from cerebral ventricular walls found inside the brain, the external ventricular system, or in ependymal cells blocked in the brain parenchyma during embryonic development [2-4]. IE's account for 1.2%-7.8% of intracranial tumors. They have a poorer overall survival, compared with spinal ependymomas [5, 6]. Incidence of IE's is greater in males than in females [7]. IE's commonly occur in children, accounting for 6%-10% of intracranial tumors [6, 8]. The 2016 World Health Organization (WHO) classification of ependymal tumors categorized sub-ependymomas and myxopapillary ependymomas as Grade I. Ependymomas, including papillary, clear cell, and tanycytic vari-

ants, are classified as Grade II. RELA fusion-positive ependymomas are classified as Grade II or III. Anaplastic ependymomas, the most malignant histological type, are classified as Grade III [9]. Epidemiological data shows that 5-year and 10-year overall survival rates are 83.4% and 79.1%, respectively [10].

Precision medicine is defined as treatment according to distinguishing characteristics of different patients with the same disease. Characteristics may be unique but not limited to one person. These include age, gender, race, histological grade, tumor size, genomics, microbiome, and social factors, such as geography, socioeconomic status, lifestyles, and environmental exposure [11-13]. Prognostic factors for IE include age, gender, histological grade, tumor location, site-specific molecular genetics,

## Geographical diversity of intracranial ependymoma



**Figure 1.** Inclusion and exclusion chart.

extent of resection, and adjuvant radiotherapy [14-17].

The present study reviewed clinical data from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, comprising a large population of patients from the United States. The current study investigated the effect of social factors on overall survival rates of patients with IE, identifying geographical distribution as a potential prognostic indicator of IE.

### Materials and methods

#### Database and patient population

Retrospective analysis was conducted using SEER Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) research data: Incidence-SEER 18 Registries Research Data, November 2017 Submission (1973-2015), National Cancer Institute, Division of Cancer Control and Population Sciences (DC-CPS), Surveillance Research Program, Surveillance Systems Branch, released in April 2018.

The SEER database follows-up patient survival every year. It provides data, such as basic information of patients, extent of the tumors, WHO grades, metastasis at the time of diagnosis, surgery conditions, and marital status. However, the database does not contain information concerning patient physical conditions, clinical symptoms, postoperative recovery, or other adjuvant treatments.

In the present study, patients diagnosed between 1973 and 2015 were selected, aiming to

improve the accuracy of survival analysis. All patients with IE were confirmed histologically and tumor behavior was identified as malignant. Primary tumors were confirmed according to international rules and originated from the brain. Cause of death was due to brain and CNS incidents. Patients that were offered active follow-ups and explicit survival results were included. Patients with benign or borderline tumors, as well as those with more than three malignant tumors, were excluded.

#### Variable collection

Patients with IE were included from the SEER database based on International Classification of Disease in Oncology 3<sup>rd</sup> edition (ICD-O-3) with codes 9391, 9392, 9393, and 9394. Prognostic factors were divided into three categories: (1) Personal basic factors: Age (>18 years or ≤ 18 years), gender, and race; (2) Clinical factors: Primary laterality (one site or paired site), histological grade, tumor size (>4 cm or ≤ 4 cm), tumor location (supratentorial, infratentorial, ventricle, across the velarium, and others), summary stage (unknown/unstaged was excluded from analysis), surgical resection (yes or no); and (3) Social factors: Marital status (divorced, separated, and single (never married or widowed) were combined to form the single group), insurance status (insured/no specifics were included in the insured group), rural-urban continuum conditions, and geographical distribution (Northeast included Connecticut and New Jersey, Midwest included Michigan and Iowa, South included Georgia, Kentucky, and Louisiana, and West included California, Utah, New Mexico, Washington, Hawaii, and Alaska).

#### Statistical analysis

Descriptive statistical methods were applied to summarize demographics and tumor characteristics of patients with IE. Kaplan-Meier survival analysis with log-rank tests were used to analyze patient 5-year survival rates and overall survival. Cox's proportional hazards regres-

## Geographical diversity of intracranial ependymoma

**Table 1.** Characteristics of patients with IE

Subgroup	Number of patients	%	5-year survival rate (%)
Age (years)			
<18 yr	1023	48.3	71.5
≥18 yr	1095	51.7	73.8
Gender			
Female	987	46.6	75.3
Male	1131	53.4	70.3
Race			
White	1724	82.1	72.9
Black	223	10.6	68.0
Other	153	7.3	75.2
Laterality			
One side	2094	98.9	72.6
Paired site	24	11	74.0
Grade			
Well differentiated	83	9.6	77.6
Moderately differentiated	253	29.3	88.7
Poorly differentiated	89	10.3	43.5
Undifferentiated	438	50.8	62.3
Tumor size			
≤40 mm	639	48.6	80.2
>40 mm	676	51.4	73.8
Location			
Supratentorial	429	26.4	73.0
Infratentorial	325	17.4	76.9
Ventricle	585	31.4	79.7
Across velarium	62	3.3	60.4
Others	402	21.5	75.3
Summary stage			
Distant	65	3.7	71.7
Localized	1437	81.3	75.3
Regional	266	15.0	69.9
Surgical resection			
No	95	4.5	65.4
Yes	2000	95.5	73.3
Marital			
Single	1453	70.4	71.8
Married	610	29.6	73.5
Insurance			
Any Medical	229	25.9	75.5
Insured	626	70.9	84.6
Uninsured	28	3.2	74.2
Rural-Urban Continuum			
Metro	1889	89.2	73.0
Nonmetro	229	10.8	71.4
Geographical distribution			
Northeast	333	15.7	74.8
Midwest	277	13.1	64.8
South	342	16.1	79.6
West	1166	55.1	72.0

sion model was applied to univariate and multivariate analyses. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. Propensity score matching (PSM) analysis was performed, further adjusting potential baseline confounding factors. Two-sided *P*-values <0.05 are considered statistically significant. Statistical analysis was carried out using SPSS version 22.0 (IBM Corp, Armonk, NY) and GraphPad Prism version 6 (GraphPad Software Inc.).

### Results

#### Study characteristics

A total of 2,691 IE patients, diagnosed between 1973 and 2015, were initially eligible. Of these, 115 patients were excluded due to unclear histology or because they were inconsistent with international rules. Another 25 patients were lost to follow-up and 45 patients had benign or borderline tumors. Two patients had more than three malignant tumors and 386 patients died of causes not related to the brain or CNS. The remaining 2,118 patients were included in the current study (**Figure 1**). Patients with incomplete IE information and individual subgroup information were excluded. Therefore, the number of patients in each subgroup displayed different statistics. Characteristics of patients with IE are summarized in **Table 1**. Most patients were white (82.1%), in which the 5-year survival rate was 72.9%. Over 90% of patients received surgical treatment. Five-year survival rates in the Northeast, Midwest, South, and West were 74.8%, 64.8%, 79.6%, and 72.0%, respectively (**Table 1**).

#### Survival differences

A prognostic examination of personal, clinical, and social factors was conducted, aiming to identify prognostic factors in patients with IE. Consistent with previous reports, several personal and clinical factors, including gender, race, tumor size, tumor location, histological grade, and surgical resection, were significantly correlated with IE patient survival [4, 14,

## Geographical diversity of intracranial ependymoma

**Table 2.** Univariate Cox proportional hazard regression analysis of risk factors among patients with IE

Subgroup	HR	95% CI	P value
<b>Age (years)</b>			
<18	1.01	0.87-1.18	0.859
≥18	1.00	Reference	
<b>Gender</b>			
Female	0.81	0.69-0.95	0.008
Male	1.00	Reference	
<b>Race</b>			
White	1.28	0.92-1.79	0.143
Black	1.50	1.02-2.23	0.042
Other	1.00	Reference	
<b>Laterality</b>			
One side	1.22	0.51-2.94	0.659
Paired site	1.00	Reference	
<b>Grade</b>			
Well differentiated	0.53	0.34-0.82	0.005
Moderately differentiated	0.30	0.21-0.43	<0.001
Poorly differentiated	1.53	1.11-2.12	0.010
Undifferentiated	1.00	Reference	
<b>Tumor size</b>			
≤40 mm	0.79	0.63-0.98	0.032
>40 mm	1.00	Reference	
<b>Location</b>			
Supratentorial	1.07	0.84-1.37	0.589
Infratentorial	0.92	0.69-1.22	0.555
Ventricle	0.74	0.58-0.95	0.018
Across velarium	1.65	1.07-2.55	0.023
Others	1.00	Reference	
<b>Summary stage</b>			
Distant	0.95	0.58-1.54	0.829
Localized	0.76	0.60-0.96	0.021
Regional	1.00	Reference	
<b>Surgical resection</b>			
No	1.46	1.05-2.03	0.024
Yes	1.00	Reference	
<b>Marital</b>			
Single	1.03	0.87-1.22	0.714
Married	1.00	Reference	
<b>Insurance</b>			
Any Medical	1.07	0.43-2.70	0.886
Insured	0.60	0.24-1.49	0.270
Uninsured	1.00	Reference	
<b>Rural-Urban Continuum</b>			
Metro	0.93	0.73-1.17	0.525
Nonmetro	1.00	Reference	
<b>Geographical distribution</b>			
Northeast	0.87	0.69-1.11	0.258
Midwest	1.41	1.15-1.73	0.001
South	0.77	0.60-0.98	0.033
West	1.00	Reference	


15, 17, 18], according to univariate analysis. Furthermore, two social factors were found to play potential prognostic roles. Regional stage patients showed poorer progress, compared with patients with other stages. Patients from the Midwest region showed a poorer prognosis, compared with those from other regions (**Table 2**). The effects of geographical distribution on IE patient survival were confirmed using Kaplan-Meier survival analysis and log-rank tests. As shown in **Figure 2A**, patients from the Midwest region showed a significant risk for poor survival, compared with those from the Northeast (HR = 0.62, 95% CI = 0.47-0.82), South (HR = 0.55, 95% CI = 0.41-0.72), and West (HR = 0.71, 95% CI = 0.58-0.87).

Identifying independent risk factors for survival of patients with IE, multivariate Cox regression was conducted with significant factors ( $P < 0.05$ ) from univariate analysis. Race, histological grade, and geographical distribution were found to be significant risk factors affecting survival of patients (**Table 3**). Aiming to reduce selection bias, PSM was applied for gender, race, and surgical resection. According to survival analysis, patients from the Midwest region had a shorter survival, compared with those from the Northeast (HR = 0.62,  $P = 0.001$ ), South (HR = 0.55,  $P < 0.0001$ ), and West (HR = 0.71,  $P = 0.001$ ). Similarly, after conducting PSM for gender, race, and surgery status, patients from the Midwest had worse survival rates, compared with those from the Northeast (HR = 0.50,  $P < 0.0001$ ), South (HR = 0.54,  $P < 0.0001$ ), and West (HR = 0.52,  $P = 0.0001$ ) (**Figure 2B-D**). Although race and histological grade have been reported to be independent prognostic factors for IE [18, 19], the current study identified geographical distribution as a novel social independent prognostic factor for IE.

### Discussion

Most current cancer research has focused on personal and clinical factors. The association between social factors and prognosis of cancer patients is often overlooked. The present study analyzed personal, clinical, and social characteristics of patients with IE selected from the SEER database. The current study also confirmed current IE prognostic factors, including race and histological grade. Present results

## Geographical diversity of intracranial ependymoma



**Figure 2.** Kaplan Meier curves of patients stratified by all different geographical regions (A) and survival probability of patients for matched age, gender, race, and surgical resection matched between the Midwest and Northeast (B), South (C), and West (D), respectively.

suggest geographical distribution as a new independent prognostic factor.

Gastric cancer is a typical regional high-risk cancer in East Asia, including South Korea, China, and Japan [20, 21]. However, incidence of gastric cancer has sharply decreased in Japanese immigrants in Hawaii, indicating that different lifestyles and modifiable factors affect the incidence frequency of gastric cancer [22]. Substantial evidence from cohort studies has strongly suggested that salt intake and *Helicobacter pylori* infections play synergistic roles in the occurrence and development of gastric cancer [21]. Environmental exposure has also been associated with geological characteristics of high mortality clusters, including environmental exposure to naturally occurring heavy metals [23, 24]. Moreover, lifestyle fac-

tors, such as alcohol consumption, smoking, and low fruit intake, have been reported as other potential risk factors for gastric cancer [22, 25].

Similarly, there is an obvious geographical aggregation in the morbidity and mortality of esophageal cancer [26]. Incidence and mortality rates of esophageal cancer are especially high in Henan and Hebei Provinces of North China [27]. The types and quality of the drinking water, as well as dietary habits, are related to the high morbidity and mortality rates of esophageal cancer in these areas. Use of tobacco and the consumption of alcohol, hot food, hard and rough food, and fast food have been associated with an increased likelihood of developing esophageal cancer [28, 29]. Moreover, *N*-nitroso compounds, found in pickled vegeta-

## Geographical diversity of intracranial ependymoma

**Table 3.** Multivariate Cox proportional hazard regression analysis of risk factors among patients with IE

Subgroup	HR	95% CI	P value
<b>Gender</b>			
Female	0.74	0.53-1.03	0.076
Male	1.00	Reference	
<b>Race</b>			
White	1.89	0.98-3.66	0.058
Black	2.56	1.20-5.46	0.015
Other	1.00	Reference	
<b>Grade</b>			
Well differentiated	0.51	0.24-1.05	0.067
Moderately differentiated	0.25	0.15-0.42	<0.001
Poorly differentiated	1.43	0.88-2.32	0.152
Undifferentiated	1.00	Reference	
<b>Tumor size</b>			
≤40 mm	0.99	0.70-1.40	0.944
>40 mm	1.00	Reference	
<b>Location</b>			
Supratentorial	1.32	0.59-2.99	0.502
Infratentorial	1.51	0.66-3.44	0.327
Ventricle	1.76	0.77-4.02	0.182
Across velarium	1.66	0.66-4.17	0.282
Others	1.00	Reference	
<b>Summary stage</b>			
Distant	1.15	0.48-2.78	0.758
Localized	0.67	0.28-1.59	0.362
Regional	1.00	Reference	
<b>Surgical resection</b>			
No	1.77	0.74-4.26	0.203
Yes	1.00	Reference	
<b>Geographical distribution</b>			
Northeast	0.41	0.19-0.88	0.023
Midwest	1.88	0.51-1.54	0.657
South	0.82	0.53-1.27	0.373
West	1.00	Reference	

bles and barbecued food, have also been shown to play an important role in the induction of esophageal cancer [30].

Nasopharyngeal carcinoma is a rare cancer. However, it occurs frequently in South China. It exhibits a unique morbidity and mortality in Guangdong and Guangxi Provinces [31]. It is believed to be related to geological environment properties and traditional lifestyles [32]. In these areas, patients with the disease are frequently infected with the Epstein-Barr virus. Moreover, the nickel-rich soil directly influences

morbidity and mortality rates of nasopharyngeal carcinoma [33, 34]. Commonly eaten foods, such as salted fish, often contain a high quantity of carcinogens (e.g., nitrosamines) that increase incidence rates of nasopharyngeal carcinoma in South China [35].

Differences in geographical distribution could also be reflected in climate conditions. Many studies have demonstrated the effects of climate on human health [36]. Specific climate conditions, such as heat waves, sunshine, and cold exposure, could increase mortality [36, 37]. The weakened physiology of cancer patients makes them more susceptible to weather conditions, which may lead to death in patients with advanced cancers [38].

Precision medicine represents an important focus of disease management. Individualized treatment protocols have been developed, based on specific factors, and the roles of social factors may have been underestimated [13]. However, the database used in the present study lacked social information, including lifestyles, dietary habits, family history, microbiome, and environmental exposure. Therefore, further data collection and research are required.

The current study had many limitations. First, PSM analysis was not applied to all influential factors. This was due to a low number of patients with ependymomas. Therefore, selection bias could not be minimized. Second, characteristic information was not available for some IE patients in the SEER database. In addition, information may have been lacking for other factors that cause diversity in survival, such as family history, genetic profiles, and disease presentation. Third, there was no information concerning radiotherapy. This may be a significant prognostic factor in patients with IE. Fourth, factors such as climate, lifestyle, and environmental exposure may have confounded present results.

In summary, present results suggest that race, histological grade, and geographical distribution were significant prognostic factors for patients with IE. Patients in Midwest USA showed poorer survival, compared with those in the Northeast, South, and West. This is the first report showing the effects of geographical distribution for IE. Present findings may be beneficial for precise treatment for patients with IE.

## Acknowledgements

We would like to acknowledge the Surveillance, Epidemiology, and End Results (SEER) Program for providing the dataset for analysis. This work was supported by the General Program of the National Natural Science Foundation of China (No. 81572891), Youth Program of the National Science Foundation of China (No. 81702481), and Natural Science Foundation of Tianjin (No. 15JCQNJC44800).

## Disclosure of conflict of interest

None.

**Address correspondence to:** Wenliang Li, Department of Neurosurgery, Tianjin Medical University Cancer Hospital and Institute, Key Laboratory of Cancer Prevention and Therapy of Tianjin, National Clinical Research Center for Cancer, Tianjin 300060, China. E-mail: liwenliang2338@163.com; Xun Jin, Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Hospital and Institute, Key Laboratory of Cancer Prevention and Therapy of Tianjin, National Clinical Research Center for Cancer, Tianjin 300060, China. E-mail: jinx2345@163.com

## References

- [1] Chen L, Zou X, Wang Y, Mao Y and Zhou L. Central nervous system tumors: a single center pathology review of 34,140 cases over 60 years. *BMC Clin Pathol* 2013; 13: 14.
- [2] Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, Jouveta A and Figarella-Branger D. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. *Neuro Oncol* 2010; 12: 976-984.
- [3] Nowak A and Marchel A. Surgical treatment of intraventricular ependymomas and subependymomas. *Neurol Neurochir Pol* 2012; 46: 333-343.
- [4] Sayegh ET, Aranda D, Kim JM, Oh T, Parsa AT and Oh MC. Prognosis by tumor location in adults with intracranial ependymomas. *J Clin Neurosci* 2014; 21: 2096-2101.
- [5] Dutzmann S, Schatlo B, Lobrinus A, Murek M, Wostrack M, Weiss C, Schaller K, Raabe A, Meyer B, Goldbrunner R, Franz K, Seifert V and Senft C. A multi-center retrospective analysis of treatment effects and quality of life in adult patients with cranial ependymomas. *J Neurooncol* 2013; 114: 319-327.
- [6] Cage TA, Clark AJ, Aranda D, Gupta N, Sun PP, Parsa AT and Auguste KI. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. *J Neurosurg Pediatr* 2013; 11: 673-681.
- [7] Ruda R, Reifenberger G, Frappaz D, Pfister SM, Laprie A, Santarius T, Roth P, Tonn JC, Soffietti R, Weller M and Moyal EC. EANO guidelines for the diagnosis and treatment of ependymal tumors. *Neuro Oncol* 2018; 20: 445-456.
- [8] Lillard JC, Venable GT, Khan NR, Tatevossian RG, Dalton J, Vaughn BN, Klimo P Jr. Pediatric supratentorial ependymoma: surgical, clinical, and molecular analysis. *Neurosurgery* 2018.
- [9] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW. The 2016 world health organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol* 2016; 131: 803-820.
- [10] Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2009-2013. *Neuro Oncol* 2016; 18: v1-v75.
- [11] Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, Jouveta A and Guyotat J. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. *Brain* 2007; 130: 1338-1349.
- [12] Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, Magli A, Franzin A, Basso U and Villa E. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. *Cancer* 2004; 100: 1221-1229.
- [13] Sengupta R and Honey K. AACR cancer progress report 2018: harnessing research discoveries for patient benefit. *Clin Cancer Res* 2018; 24: 4351.
- [14] McGuire CS, Sainani KL and Fisher PG. Both location and age predict survival in ependymoma: a SEER study. *Pediatr Blood Cancer* 2009; 52: 65-69.
- [15] Massimino M, Buttarelli FR, Antonelli M, Gandola L, Modena P and Giangaspero F. Intracranial ependymoma: factors affecting outcome. *Future Oncol* 2009; 5: 207-216.
- [16] Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Puchihewa C, Johann P, Reimand J, Warnatz HJ, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman LM, Donson AM, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong TS, Gupta N, Allen JC, Karajannis MA, Zagzag D, Hasselblatt M, Kulozik AE, Witt O, Collins VP, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo ML, von

## Geographical diversity of intracranial ependymoma

- Deimling A, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Kool M and Pfister SM. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. *Cancer Cell* 2015; 27: 728-743.
- [17] Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K; Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. *Acta Neuropathol* 2012; 123: 727-38.
- [18] Bates JE, Choi G and Milano MT. Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. *J Neurooncol* 2016; 129: 251-258.
- [19] Ye J, Zhu J, Yan J, Chen P, Wan Z, Chen F, Zhang L, Qian J and Luo C. Analysis on therapeutic outcomes and prognostic factors of intracranial ependymoma: a report of 49 clinical cases in a single center. *Neurol Sci* 2015; 36: 2253-2261.
- [20] Sugano K. Screening of gastric cancer in asia. *Best Pract Res Clin Gastroenterol* 2015; 29: 895-905.
- [21] Shin JY, Kim J, Choi KS, Suh M, Park B and Jun JK. Relationship between salt preference and gastric cancer screening: an analysis of a nationwide survey in Korea. *Cancer Res Treat* 2016; 48: 1037-1044.
- [22] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394-424.
- [23] Montero-Oleas N, Nunez-Gonzalez S and Simancas-Racines D. The remarkable geographical pattern of gastric cancer mortality in Ecuador. *Cancer Epidemiol* 2017; 51: 92-97.
- [24] Torres J, Correa P, Ferreccio C, Hernandez-Suarez G, Herrero R, Cavazza-Porro M, Dominguez R and Morgan D. Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of pacific latin America. *Cancer Causes Control* 2013; 24: 249-256.
- [25] Choi YJ, Lee DH, Han KD, Kim HS, Yoon H, Shin CM, Park YS and Kim N. The relationship between drinking alcohol and esophageal, gastric or colorectal cancer: a nationwide population-based cohort study of South Korea. *PLoS One* 2017; 12: e0185778.
- [26] He YT, Hou J, Chen ZF, Qiao CY, Song GH, Meng FS, Jin HX and Chen C. Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China. *Eur J Cancer Prev* 2008; 17: 71-76.
- [27] Li YY, Du LB, Hu XQ, Jaiswal S, Gu SY, Gu YX and Dong HJ. A suggested framework for conducting esophageal cancer screening in China. *J Dig Dis* 2018; 19: 722-729
- [28] Rolland D, Raharijaona M, Barbarat A, Houllatte R and Thieblemont C. Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. *Anticancer Res* 2010; 30: 3951-3957.
- [29] Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Nutrient intake and risk of subtypes of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2001; 10: 1055-1062.
- [30] Tian D, Mo SJ, Han LK, Cheng L, Huang H, Hao S, Guan YL, Jiang KY, Deng JY, Feng HH, Wen HY and Fu MY. Investigation of dietary factors and esophageal cancer knowledge: comparison of rural residents in high- and low-incidence areas. *Sci Rep* 2018; 8: 4914.
- [31] Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM and Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. *Chin J Cancer* 2017; 36: 90.
- [32] Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX and Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. *Chin J Cancer* 2014; 33: 381-387.
- [33] Tham T. Human papillomavirus and world health organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in southern China. *Cancer* 2019; 125: 161
- [34] Lin K, Shen W, Shen Z, Wu Y and Lu S. Dietary exposure and urinary excretion of total N-nitroso compounds, nitrosamino acids and volatile nitrosamine in inhabitants of high- and low-risk areas for esophageal cancer in southern China. *Int J Cancer* 2002; 102: 207-211.
- [35] Xu ZX, Lin ZX, Fang JY, Wu KS, Du PL, Zeng Y, Tang WR, Xu XL and Lin K. Mortality characteristic and prediction of nasopharyngeal carcinoma in China from 1991 to 2013. *Asian Pac J Cancer Prev* 2015; 16: 6729-6734.
- [36] Kim YS, Park DK, Hwang IC and Ahn HY. Daily weather conditions and anticipated death from cancer. *Iran J Public Health* 2018; 47: 591-596.
- [37] Gorjanc ML, Flanders WD, VanDerslice J, Hersh J and Malilay J. Effects of temperature and snowfall on mortality in pennsylvania. *Am J Epidemiol* 1999; 149: 1152-1160.
- [38] McGeehin MA and Mirabelli M. The potential impacts of climate variability and change on temperature-related morbidity and mortality in the United States. *Environ Health Perspect* 2001; 109 Suppl 2: 185-189.